Total Payments
$51,940
2024 Payments
$6,407
Companies
17
Transactions
190
Medicare Patients
1,258
Medicare Billing
$438,479
Payment Breakdown by Category
Other$41,868 (80.6%)
Food & Beverage$5,968 (11.5%)
Travel$3,984 (7.7%)
Education$119.03 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,868 | 22 | 80.6% |
| Food and Beverage | $5,968 | 123 | 11.5% |
| Travel and Lodging | $3,984 | 19 | 7.7% |
| Education | $119.03 | 26 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Melinta Therapeutics, LLC | $48,235 | 86 | $0 (2024) |
| Insmed, Inc. | $2,342 | 65 | $0 (2020) |
| CIPLA USA INC. | $377.00 | 1 | $0 (2019) |
| Allergan, Inc. | $255.30 | 8 | $0 (2020) |
| Cumberland Pharmaceuticals, Inc. | $191.72 | 5 | $0 (2022) |
| Merck Sharp & Dohme LLC | $175.52 | 6 | $0 (2024) |
| ViiV Healthcare Company | $80.87 | 4 | $0 (2020) |
| Nabriva Therapeutics, plc | $56.42 | 3 | $0 (2020) |
| Astellas Pharma US Inc | $48.80 | 2 | $0 (2024) |
| ABBVIE INC. | $48.02 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,407 | 19 | Melinta Therapeutics, LLC ($6,294) |
| 2023 | $31,515 | 48 | Melinta Therapeutics, LLC ($31,387) |
| 2022 | $10,383 | 21 | Melinta Therapeutics, LLC ($10,346) |
| 2021 | $402.38 | 13 | Melinta Therapeutics, LLC ($208.18) |
| 2020 | $2,855 | 88 | Insmed, Inc. ($2,342) |
| 2019 | $377.00 | 1 | CIPLA USA INC. ($377.00) |
All Payment Transactions
190 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/09/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/20/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/04/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $28.51 | General |
| Category: Infectious Diseases | ||||||
| 06/17/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: ANTIBIOTICS | ||||||
| 06/17/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Food and Beverage | In-kind items and services | $32.70 | General |
| Category: ANTIBIOTICS | ||||||
| 05/23/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $124.14 | General |
| Category: ANTIFUNGALS | ||||||
| 05/08/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $31.41 | General |
| Category: ANTIFUNGALS | ||||||
| 03/21/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $27.05 | General |
| Category: ANTIFUNGALS | ||||||
| 03/19/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: ANTIBIOTICS | ||||||
| 03/19/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Travel and Lodging | Cash or cash equivalent | $43.76 | General |
| Category: ANTIBIOTICS | ||||||
| 03/19/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Food and Beverage | In-kind items and services | $25.43 | General |
| Category: ANTIBIOTICS | ||||||
| 03/15/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: ANTIBIOTICS | ||||||
| 03/15/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Travel and Lodging | Cash or cash equivalent | $74.58 | General |
| Category: ANTIBIOTICS | ||||||
| 03/15/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Food and Beverage | In-kind items and services | $32.70 | General |
| Category: ANTIBIOTICS | ||||||
| 02/28/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $34.71 | General |
| Category: ANTIFUNGALS | ||||||
| 01/29/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $5.17 | General |
| Category: ANTIFUNGALS | ||||||
| 01/08/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Vabomere | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: ANTIFUNGALS | ||||||
| 12/16/2023 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Rezzayo, Vabomere | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: ANTIBIOTICS | ||||||
| 12/15/2023 | Melinta Therapeutics, LLC | Vabomere (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: ANTIBIOTICS | ||||||
| 12/15/2023 | Melinta Therapeutics, LLC | Vabomere (Drug) | Food and Beverage | In-kind items and services | $30.87 | General |
| Category: ANTIBIOTICS | ||||||
| 12/14/2023 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: ANTIBIOTICS | ||||||
| 12/14/2023 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Travel and Lodging | Cash or cash equivalent | $30.13 | General |
| Category: ANTIBIOTICS | ||||||
| 12/14/2023 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: ANTIBIOTICS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 152 | 662 | $216,222 | $58,475 |
| 2022 | 3 | 318 | 1,622 | $503,960 | $141,154 |
| 2021 | 3 | 52 | 117 | $38,925 | $11,643 |
| 2020 | 14 | 736 | 232,154 | $915,095 | $227,207 |
Total Patients
1,258
Total Services
234,555
Medicare Billing
$438,479
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 81 | 488 | $163,808 | $44,747 | 27.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 134 | $30,172 | $8,408 | 27.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 39 | 40 | $22,242 | $5,320 | 23.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 156 | 1,217 | $369,968 | $103,948 | 28.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 119 | 126 | $74,844 | $20,425 | 27.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 43 | 279 | $59,148 | $16,780 | 28.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 68 | $20,672 | $6,103 | 29.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 22 | $13,068 | $3,891 | 29.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 27 | $5,185 | $1,649 | 31.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 44 | 793 | $145,119 | $46,347 | 31.9% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2020 | 16 | 226,512 | $475,539 | $38,847 | 8.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 107 | 435 | $78,280 | $37,694 | 48.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 174 | 287 | $41,860 | $24,665 | 58.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 48 | 492 | $41,967 | $18,465 | 44.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 106 | 110 | $27,560 | $18,373 | 66.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 66 | 255 | $34,425 | $15,398 | 44.7% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2020 | 14 | 263 | $13,150 | $6,672 | 50.7% |
| G0181 | Physician supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of c | Office | 2020 | 27 | 66 | $10,890 | $5,861 | 53.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 37 | 37 | $11,080 | $5,035 | 45.4% |
| 15852 | Dressing change under anesthesia | Office | 2020 | 20 | 97 | $12,041 | $3,848 | 32.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 44 | 56 | $6,995 | $3,283 | 46.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis | Office | 2020 | 16 | 88 | $4,312 | $1,573 | 36.5% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2020 | 17 | 2,663 | $11,877 | $1,146 | 9.6% |
About Dr. Shaker Itani, M.D
Dr. Shaker Itani, M.D is a Infectious Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538193826.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shaker Itani, M.D has received a total of $51,940 in payments from pharmaceutical and medical device companies, with $6,407 received in 2024. These payments were reported across 190 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($41,868).
As a Medicare-enrolled provider, Itani has provided services to 1,258 Medicare beneficiaries, totaling 234,555 services with total Medicare billing of $438,479. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Los Angeles, CA
- Active Since 07/10/2006
- Last Updated 12/12/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1538193826
Products in Payments
- Kimyrsa (Drug) $32,043
- Vabomere (Drug) $15,860
- Arikayce (Drug) $1,742
- ZEMDRI (PLAZOMICIN) (Drug) $377.00
- Rezzayo (Drug) $254.65
- VIBATIV (Drug) $191.72
- AVYCAZ (Drug) $169.87
- ZERBAXA (Drug) $105.25
- DALVANCE (Drug) $89.92
- DOVATO (Drug) $80.87
- Orbactiv (Drug) $77.31
- DIFICID (Drug) $58.52
- Xenleta (Drug) $56.42
- TEFLARO (Drug) $43.53
- Fetroja (Drug) $37.62
- Cresemba (Drug) $28.51
- CRESEMBA (Drug) $20.29
- EGRIFTA (Drug) $17.89
- GIAPREZA (Drug) $15.88
- NUZYRA (Drug) $15.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Los Angeles
Peter Ruane, Md, MD
Infectious Disease — Payments: $866,043
Infectious Disease $866,043
Dr. Jay Gladstein, M.d, M.D
Infectious Disease — Payments: $732,232
Infectious Disease $732,232
Otto Yang, Md, MD
Infectious Disease — Payments: $477,960
Infectious Disease $477,960
Irving Posalski, M.d, M.D
Infectious Disease — Payments: $235,663
Infectious Disease $235,663
Dr. Fred Sattler, M.d, M.D
Infectious Disease — Payments: $69,230
Infectious Disease $69,230
Jim Nomura, Md, MD
Infectious Disease — Payments: $40,310
Infectious Disease $40,310